Almirall announces licensing agreement to accelerate antibody drug discovery

pharmafile | January 31, 2022 | News story | Sales and Marketing  

Almirall has announced a multi-target licensing agreement with Ablexis, focussed on licensing its AlivaMab Mouse technology, and a research collaboration with AlivaMab Discovery Services, to accelerate antibody drug discovery and development.

“These agreements are in line with Almirall’s vision to develop innovative treatment options for patients suffering from severe skin diseases. AlivaMab Discovery Services’ profound know-how in antibody discovery and engineering together with Almirall’s expertise in dermatology will strongly accelerate the development of differentiated treatments to help patients get closer to their goal of leading a healthy life,” shared Dr Thomas Huber, Research Director at Almirall. “The agreements highlight the company’s commitment to early biologics discovery to provide the best solutions to skin conditions through novel science.”

Almirall is a global biopharmaceutical company focused on skin health, which under the terms of the license, is granted exclusive rights to Ablexis’ AlivaMab Mouse technology for the discovery, development, and commercialisation of innovative antibody drugs. Ablexis is a biopharmaceutical company.

Additionally, Almirall will collaborate with AlivaMab Discovery Services (ADS) to conduct the research, leveraging ADS’ expertise of antibody drug discovery and engineering, using the AlivaMab Mouse technology, a state-of-art platform for the generation of human therapeutic antibodies. AlivaMab Discovery Services is a leader in the discovery and engineering of antibody therapeutics.

“Almirall joins our rapidly expanding list of high-quality partners that leverage the discovery, engineering and developability assessment capabilities of ADS, especially for challenging targets, functional design goals and advanced modalities,” said Justin Mika, CEO at AlivaMab Discovery Services. “Our partners appreciate how our team’s expertise, combined with the proven AlivaMab Mouse platform, significantly improves the probability of success and shortens timelines in discovery and development. We look forward to supporting Almirall’s efforts to help patients with dermatological conditions.”

Related Content

No items found

Latest content